Treatment and Monitoring of Chronic Hepatitis B Infection
For chronic hepatitis B, initiate long-term treatment with entecavir, tenofovir disoproxil, or tenofovir alafenamide in patients with HBV DNA ≥2,000 IU/ml plus elevated ALT and/or moderate histological lesions, and treat all cirrhotic patients with detectable HBV DNA. 1
Treatment Indications
Standard Treatment Criteria
- Definite treatment indication: HBV DNA ≥2,000 IU/ml combined with elevated ALT levels and/or at least moderate histological liver lesions 1
- Cirrhotic patients: All patients with cirrhosis and detectable HBV DNA require treatment regardless of ALT or HBV DNA level 1
- Adolescents: Treatment can be initiated in patients over 12 years old meeting standard criteria 1
Evolving Treatment Landscape
The 2024 WHO guidelines have expanded treatment indications beyond traditional criteria, moving toward a more inclusive approach to increase treatment coverage from the current <20% to 80% of eligible patients 1. However, this represents a public health approach that differs from the more personalized strategies recommended by liver societies 1. The EASL guidelines maintain more conservative, individualized treatment thresholds based on the complex natural history of chronic hepatitis B, which includes five distinct phases with different prognoses 1.
Special Populations Requiring Treatment
- Pregnant women: High viremia cases to prevent mother-to-child transmission 1
- Immunosuppression/chemotherapy: Prophylaxis to prevent HBV reactivation 1
- HBeAg-negative patients with normal ALT: Recent evidence shows TAF achieves complete viral suppression (HBV DNA <20 IU/mL in 100% of patients at 48 weeks) and may delay fibrosis progression, suggesting potential benefit for early treatment in this population 2
First-Line Treatment Options
Nucleos(t)ide Analogues (Preferred)
Use potent agents with high barrier to resistance for long-term administration: 1
- Entecavir
- Tenofovir disoproxil fumarate (TDF)
- Tenofovir alafenamide fumarate (TAF)
These three agents represent the treatment of choice due to their potency and resistance profiles 1. TAF specifically demonstrates excellent viral suppression with 100% of treated patients achieving HBV DNA below 20 IU/mL after 48 weeks 2.
Alternative Option
- Pegylated interferon-alfa: Can be considered in mild to moderate chronic hepatitis B patients, though nucleos(t)ide analogues remain preferred 1
What NOT to Do
Combination therapies are not generally recommended 1
Monitoring Protocol
During Treatment
Monitor every 12-24 weeks during active antiviral therapy: 1
- HBV DNA levels: Essential for assessing virological response
- ALT levels: Track liver inflammation
- HBeAg/anti-HBe status: Document seroconversion if applicable
- HBsAg levels: Track toward optimal endpoint of HBsAg loss
Critical early monitoring at weeks 12 and 24: Early viral response predicts sustained response and antiviral resistance risk 3. Use real-time PCR assays with 7-8 log₁₀ dynamic range for accurate quantification 3.
Common Pitfall in Real-World Practice
Despite guideline recommendations, monitoring rates are suboptimal in routine care settings. Among US patients, only 77% receive recommended ALT monitoring and 85% receive HBV DNA monitoring before treatment, dropping to 63% and 36% respectively after treatment initiation 4. Do not reduce monitoring frequency after treatment starts—maintain vigilance throughout therapy. 4
After Treatment/Long-Term Follow-Up
Monitor every 6-12 months after treatment cessation or in untreated patients: 1
- HBV DNA levels
- ALT levels
- HBsAg status
- Hepatocellular carcinoma (HCC) surveillance: All patients with chronic HBV infection remain at increased risk of HCC and cirrhosis progression regardless of treatment status 1
Post-Liver Transplant Monitoring
For patients who underwent liver transplantation for hepatitis B, current guidelines suggest selected low-risk patients (low HBV DNA at transplant, no HCC, no HIV/HDV coinfection) can discontinue hepatitis B immunoglobulin (HBIG) therapy at 6-12 months post-transplant while continuing antiviral therapy with monitoring 5. Patients on lamivudine should be switched to tenofovir for superior resistance profile 5.
Treatment Goals and Endpoints
Primary Goal
Long-term suppression of HBV replication to improve survival and quality of life by preventing disease progression and HCC development 1
Treatment Endpoints
- Main endpoint: Sustained HBV DNA suppression 1
- Optimal endpoint: HBsAg loss with or without anti-HBs seroconversion (immunologic cure) 1, 6
Key Clinical Considerations
Treatment Gap
Nearly one-third of patients with definite indications for antiviral therapy remain untreated in routine practice 4. Actively identify and treat eligible patients—do not allow patients with clear treatment indications to go untreated.
Resistance Monitoring
Antiviral resistance may emerge during long-term therapy, making continued virological monitoring essential 3. The high-barrier agents (entecavir, TDF, TAF) minimize this risk but do not eliminate it entirely 1.
Duration of Therapy
Current treatments have limited success in achieving durable endpoints, typically requiring indefinite therapy until HBsAg loss is achieved 3. The 2025 AASLD/IDSA guidelines address withdrawal of antiviral therapy, though specific criteria require careful patient selection 7.